Overview
Location
Belgium, Brussels-Capital, City of Brussels
Employees
11-50
Total raised
$42.39M
Founded date
2014
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 19, 2018 | Camel-IDS Secures €37M in Series A Funding | Camel-IDS, a Brussels, Belgium-based developer of cancer-targeted radiopharmaceuticals, secured €37m in Series A funding. The round was led by V-Bio Ventures and Gimv with participation from HealthCap, Novo Seeds, Pontifax and BioMedPartner... |
| Nov 16, 2018 | With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A funding | Interest in targeted radiation treatments was buoyed last month with Novartis’ $NVS $2.1 billion bet on Endocyte that put the spotlight on a decades-old class of drugs in the lucrative field of oncology. Belgian radiot... |
| Camel-IDS appoints Ruggero Della Bitta MD, PhD, as Chief Medical Officer | Brussels (Belgium), 8 October 2019 Camel-IDS, a privately-held biotechnology company developing novel radiopharmaceuticals, today announced the appointment of Ruggero Della Bitta MD, PhD, as Chief Medical Officer of Camel-IDS, effective Oc... |